Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Assessment of cerebrovascular reserve using acetazolamide brain perfusion SPECT in Moyamoya disease

Document Type : Original Article

Authors
Harish Goyal 1
Dhritiman Chakraborty 2
Srinivas Ananth Kumar 1
Somnath Pandey 3
1 Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education Research, Puducherry, India
2 Department of Nuclear Medicine, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
3 Quadra Medical Services Pvt Ltd, Kolkata, West Bengal, India
10.22038/aojnmb.2025.89265.1647
Abstract
Objective(s): Moyamoya disease (MMD) is a rare, progressive steno-occlusive cerebrovascular disorder characterized by impaired cerebral perfusion and an elevated risk of ischemic events.  Accurate cerebrovascular reserve (CVR) assessment is crucial for guiding surgical decision-making. This study evaluated the clinical utility of acetazolamide (ACZ)-challenged brain perfusion single-photon emission computed tomography (SPECT) in assessing CVR in patients with MMD.
Methods: We retrospectively analyzed 10 patients (6 males, four females; aged 5–65 years) with angiographically confirmed MMD who underwent baseline and post-ACZ 99mTc-ECD SPECT. Regional perfusion across 12 brain regions per patient was visually graded and classified using Rogg’s criteria (Type I–III) to assess CVR.
Results: At baseline, 78/120 regions showed normal perfusion; post-ACZ, this decreased to 72 regions, with an increase in severe hypoperfusion (from 16 to 26 regions). A total of 44 regions demonstrated improved perfusion following ACZ, indicating preserved reserve. According to Rogg’s classification, 63 regions showed Type I, 13 showed Type II, and 39 showed Type III responses. Three patients had infarcts, with two exhibiting crossed cerebellar diaschisis. In a patient who underwent revascularization, new postoperative perfusion defects developed in regions that corresponded to preoperative Type III responses.
Conclusion: ACZ-challenged SPECT effectively characterizes regional CVR in MMD. Identifying Type II and III responses is a valuable predictor for ischemic vulnerability and guides the selection of surgical candidates.
Keywords
Moyamoya disease
Acetazolamide
Brain Perfusion SPECT
Cerebrovascular reserve
Rogg’s Classification
Subjects
  1. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Archives of neurology. 1969;20(3): 288-299.
  2. Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome.  New England Journal of Medicine. 2009; 360(12):1226–1237.
  3. Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, et al. Pediatric moyamoya disease: an analysis of 410 consecutive cases. Annals of neurology. 2010; 68(1): 92-101.
  4. Derdeyn CP, Grubb RL Jr, Powers WJ. Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. 1999; 53(2): 251-259.
  5. Hirano T, Minematsu K, Hasegawa Y, Tanaka Y, Hayashida K, Yamaguchi T. Acetazolamide reactivity on 123I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: correlation with positron emission tomography parameters. Journal of Cerebral Blood Flow & Metabolism. 1994; 14(5): 763-770.
  6. Houkin K, Kamiyama H, Abe H, Takahashi A, Kuroda S. Surgical therapy for adult moyamoya disease. Can surgical revascularization prevent the recurrence of intracerebral hemorrhage? Stroke. 1996; 27(8): 1342-1346.
  7. Cho WS, Kim JE, Kim CH, Ban SP, Kang HS, Son YJ, et al. Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke. 2014; 45(10): 3025-3031.
  8. Fujimura M, Tominaga T, Kuroda S, Takahashi JC, Endo H, Ogasawara K, et al. 2021 Japanese guidelines for the management of moyamoya disease: guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society. Neurologia medico-chirurgica. 2022; 62(4): 165-170.
  9. Powers WJ, Zazulia AR. The use of positron emission tomography in cerebrovascular disease. Neuroimaging Clinics. 2003; 13(4): 741-758.
  10. He S, Wang X, Niu H, Liu Z, Zhang J, Hao X, et al. Evaluation of cerebrovascular reactivity in moyamoya disease using oxygen-dependent magnetic resonance imaging. Iscience. 2024; 27(2):108923.
  11. Li J, Jin M, Sun X, Li J, Liu Y, Xi Y, et al. Imaging of moyamoya disease and moyamoya syndrome: current status. Journal of computer assisted tomography.2019; 43(2): 257-263.
  12. Rogg J, Rutigliano M, Yonas H, Johnson DW, Pentheny S, Latchaw RE. The acetazolamide challenge: imaging techniques designed to evaluate cerebral blood flow reserve. American Journal of Roentgenology. 1989; 153(3): 605-612.
  13. Touho H, Karasawa J, Ohnishi H. Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc-HMPAO SPECT and acetazolamide in childhood Moyamoya disease. Stroke. 1996; 27(2): 282-289.
  14. Kashyap R, Mittal BR, Sunil HV, Bhattacharya A, Singh B, Mukherjee KK, et al. Tc99m-ECD brain SPECT in patients with Moyamoya disease: A reflection of cerebral perfusion status at tissue level in the disease process. Indian Journal of Nuclear Medicine. 2011; 26(2): 82-85.
  15. Sun W, Ruan Z, Dai X, Li S, Li S, Zhang J, et al. Quantifying hemodynamic changes in moyamoya disease based on two-dimensional cine phase-contrast magnetic resonance imaging and computational fluid dynamics. World Neurosurgery.2018; 120: e1301-e1309.
  16. Yu Z, Bai X, Zhang Y, Zhang G, Qiu C, Chen L, et al. Baseline hemodynamic impairment and revascularization outcome in newly diagnosed adult moyamoya disease determined by pseudocontinuous arterial spin labeling. World Neurosurgery. 2022; 165: e494-e504.
  17. Goetti R, O'Gorman R, Khan N, Kellenberger CJ, Scheer I. Arterial spin labelling MRI for assessment of cerebral perfusion in children with moyamoya disease: comparison with dynamic susceptibility contrast MRI. Neuroradiology. 2013; 55(5): 639-647.
  18. So Y, Lee HY, Kim SK, Lee JS, Wang KC, Cho BK, et al. Prediction of the clinical outcome of pediatric moyamoya disease with postoperative basal/ acetazolamide stress brain perfusion SPECT after revascularization surgery. Stroke. 2005; 36(7): 1485-1489.
  19. Baron JC, Bousser MG, Comar D, Castaigne P. Crossed cerebellar diaschisis in human supratentorial brain infarction. Transactions of the American Neurological Association. 1981; 105: 459-461.
  20. Sin DS, Kim MH, Park SA, Joo MC, Kim MS.Crossed cerebellar diaschisis: risk factors and correlation to functional recovery in intracerebral hemorrhage. Annals of Rehabilitation Medicine. 2018; 42(1): 8-17.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 14, Issue 1
January 2026
Pages 90-97